DOCSLIB.ORG

Issue #105-116, 1978

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ISSN 0146-3055 THE NLM TECHNICAL BULLETIN FORMED BY THE UNION OF THE LIBRARY NETWORK/MEDLARS TECHNICAL BULLETIN AND THE TOXLINE TECHNICAL BULLETIN JANUARY 78 NO. 105 THE CONTENTS OF THIS PUBLICATION ARE NOT COPYRIGHTED AND MAY BE FREELY REPRODUCED TABLE OF CONTENTS Page DATA BASE UPDATES 2 TECHNICAL NOTES 3 TOXLINE/TOXBACK REGENERATION 5 NLM CATALOGING SECTION USE OF THE 4TH EDITION OF NLM CLASSIFICATION 8 NEW SERIALS ANNOUNCEMENT - DECEMBER 1977 10 LIST OF MONOGRAPHS INDEXED - FEBRUARY 1978 13 TECHNICAL NOTE 231 APPENDIX A ELHILL 3 FREE TEXT STOPWORD LIST APPENDIX B U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE Public Health Service National Institutes of Health NLM TECHNICAL BULLETIN - JAN 78 FILES TOTAL DATES DATE LAST LATEST DATA BASE RECORDS COVERED UPDATED UPDATE TAG *AVLINE 5,225 1900-1978 9 FEB 78 BACK66 545,463 JAN 66-DEC 68 19 DEC 77 BACK69 649,346 JAN 69-DEC 71 19 DEC 77 BACK72 671,116 JAN 72-DEC 74 19 DEC 77 +BACK75 385,601 JAN 75-DEC 75 19 DEC 77 *CANCERLIT 113,617 JAN 63-FEB 78 14 FEB 78 7802(ED) *CANCERPROJ 18,194 1976-1977 20 DEC 77 7711(ED) *CATLINE 173,208 1965-1978 10 FEB 78 CHEMLINE 246,193 15 DEC 77 *CLINPROT 834 18 APR 77 *EPILEPSY 21,077 1945-1976 30 JAN 78 *JOURNAL AUTH 4,950 1978 MEDLINE 442,016 JAN 76-MAR 78 6 FEB 78 7803(IM) MESH VOC 14,697 1978 19 DEC 77 *NAME AUTH 95,102 1978 2 FEB 78 *RTECS 21,543 1976 1 SEP 77 SDILINE 20,066 MAR 78 6 FEB 78 *TOXLINE 409,268 6 FEB 78 7712(ST) CBAC 202,099 1974-V.26.ISS11-13 TOXBIB 87,581 1974-FEB 78 IPA 24,874 1974-NOV 77 HEEP 54,942 1974-FEB 78 PESTAB 11,076 1974-SEP 77 EMIC 19,093 1960-PRESENT ETIC 9,603 1950-PRESENT *TOXBACK 379,299 6 FEB 78 CBAC 167,668 1965-1973 TOXBIB 127,104 1968-1973 IPA 19,188 1970-1973 HEEP 24,680 1971-1973 HAPAB 12,816 1966-1973 HAYES 10,043 1940-1966 TMIC 4,552 1971-1975 TERA 13,248 1960-1974 4*+* 1) * = FILES AVAILABLE AT NLM ONLY. 2) + = CITATIONS WITH PUBLICATION YEAR OF 1975 OR EARLIER BUT ENTRY DATE OF 1976 OR 1977 ALSO INCLUDED. 3) THE BACKFILES ARE AVAILABLE ONLY THRU OFFSEARCH AT NLM AND SUNY 4) TOXBACK IS AVAILABLE ONLY THRU OFFSEARCH AT NLM. This publication, which is issued monthly, is not copyrighted and may be freely reproduced. Editor: Grace H. McCarn Direct inquiries to: MEDLARS Management Section Assistant Editors: Yvonne B, Scott National Library of Medicine Sharon L. Valley, Ph.D. 8600 Rockville Pike Technical Notes Editor: Carolyn B. Til ley Bethesda, Maryland 20014 301/496-6193 -2- NLM TECHNICAL BULLETIN - JAN 78 TECHNICAL NOTES PLEASE QUERY THE ON LINE NEWS FILES DAILY AT NLM FOR SPECIAL NOTICES AND MESSAGES Whenever applicable, the headings of each Technical Note will Include a reference to the section/page of the NLM On-line Services Reference Manual which is consid- ered roost relevant to the item being discussed (e.g., Manual I1-9). Users should keep 1n mind that the item may pertain to other sections of the Manual. TRAINING - In order to avoid conflicts with Federal holidays, the dates of two on-line services training classes have been changed: From Oct 9-13, 1978 to Oct 2-6, 1978 From Nov 6-10, 1978 to Oct 30-Nov 3, 1978. The complete schedule of training classes appeared in the July 1977 Technical Bulletin. SERLINE - An entry of "SER" in the Abstracting and Indexing field (AI) (Manual X) of SERLINE indicates that the journal was in the original group of 6,500 SERLINE journals. CHEMLINE If, while in the CHEMLINE file and attempting a "PRINT DETAILED, (Manual XIV) the message "CAN XXXXXX CONTAINS NONE OF THE ELEMENTS SPECIFIED" is received, the detailed unit record is too long for printing in the detailed format. To get around this message, do a "PRINT INCLUDE and specify the fields you want printed. PHONES - All numbers are for 10-30 cps unless otherwise noted, Addi ti ons: City Tymnet Telenet Tymnet FX Van Nuys, CA 2213/986-9503 Honolulu, HI 808/524-8110 Honolulu, HI *808/521-0611 Norfolk, VA 804/625-1430 Oklahoma City, OK 405/272-9280 Omaha, NE 402/330-1900 Providence, RI 401/274-1125 St. Petersburg, FL 813/823-8964 Syracuse, NY 315/424-9381 Tulsa, OK 918/587-0158 *120 CPS Service — Bell 212 and VADIC modems. Changes: City From To Network/Type Cincinnati, OH 513/621-7460 513/242-7040 Tymnet, C -3- NLM TECHNICAL BULLETIN - JAN 78 MESH ORGANIZATION & ADMINISTRATION SUBHEADING - The abbreviation has been changed from "OR"to "OG" because there was a conflict with the logical connector "OR." The on-line files have been updated to reflect this change. INDEXING - ACTION POTENTIALS, EVOKED POTENTIALS, MEMBRANE POTENTIALS - Indexing policy has changed. Please change the annotations in your MeSH to read NIM instead of IM. - TECHNICAL NOTE 231 - On page 13 of the September 1977NLM Technical Bulletin it was incorrectly stated that all previous indexing Technical Notes, through number 231, are available through NTIS. Technical Note 231 is no_t available through NTIS and is included with this bulletin as Appendix A. MEDLINE - BACK75 (Manual VII) - The BACK75 file of MEDLINE was created and made available to users via the "OFFSEARCH command on December 19, 1977. The file contains (1) citations with an entry date from 741205 through 751108 or (2) citations which have a 1975,or earlier, year of publication (YP), regardless of entry date. - (IM) DATA ELEMENT - This is a reminder that searchers should use the (IM) data element, not the (ED) data element to limit retrieval to a specific month(s). For example: (1) to re-create October 77 SDILINE: SS 1 /C? USER: 7710* (2) to search only 1977 input: SS 1 /C? USER: 7701 OR 7702 OR 7703 OR 7704 OR 7705 OR 7706 OR CNT 1 USER: 7707 OR 7708 OR 7709 OR 7710 OR 7711 OR 7712* The (IM) data element was added to the records beginning with July 76 input. If segments of the file are needed before this date, call the MEDLARS Management Section Service Desk for entry dates. *Note: the qualifier (IM) is not required - NEW SPECIAL LIST C - Because of its importance to the program goals of the National Institute of Neurological and Communi- cative Disorders and Stroke, citations to certain literature that has not been accepted for Index Medicus will be indexed and input to MEDLINE as special list material. Because it relates to communication disorders, this will be designated Special List C. At the outset, this will include only eight journals starting with 1978 issues. -4- NLM TECHNICAL BULLETIN - JAN 78 TOXLINE/TOXBACK REGENERATION Sharon L. Valley, Ph.D. Specialized Information Services The TOXLINE/TOXBACK files are 1n the process of being regenerated. When completed, TOXLINE will contain Information from 1974 secondary sources forward, representing approximately 380,000 documents. TOXBACK will contain Information from secondary sources prior to 1974 and will contain approximately 350,000 documents. It 1s anticipated these files will be available by March 1, 1978. There will be some changes 1n the unit record description for the regener- ated TOXLINE/TOXBACK. Specifically, these changes are: 1. Page number (PG) will be eliminated as a separate, searchable element. The pagination will still print as part of the Source (SO) field. 2. Medical Subject Headings (MH) will not be directly searchable as (MH). They will, however, be textracted Into unlterms and be searchable as text words (TW),I.e.: (TW) THIN AND LAYER AND ALL CHROMATOG: Instead of (MH) CHROMATOGRAPHY, THIN-LAYER. 3. Medical Subject Headings Tree Numbers will not be Included 1n TOXLINE, since the vocabulary changes are not "file maintained" each year. This means users will not be able to EXPLODE MeSH terms or tree numbers 1n TOXLINE. The term(s) should be entered as text words (TW) Instead. 4. The year of publication (YP) will not be rangeable, but will be searchable as Individual years, I.e., a user maylimit a search to papers published 1n either 1976 or 1977, by entering: CORRECT 5 AND 76 OR 5 AND 77 where 5 equals search statement 5. Users will not be able to enter: INCORRECT 5 AND FROM 76 TO 77. The correct example 1s a more efficient use of the computer system for this type of query. The latter type of search would be more time consuming, therefore the ranging file for "year of publication" was not created. -5- NLM TECHNICAL BULLETIN - JAN 78 5. The source and time frame field (ST) will be 4 digits, and searchable, (YYMM as year month) I.e. 7G04 for the 1978, April update. 6. In the material supplied by Chemical Abstracts Service (CAS) there will be additional Chemical Abstracts Service Registry Numbers (RN), which were CAS Indexing Information but not Included In the earlier version of TOXLINE. These additional CAS Registry Numbers will appear 1n the searchable RN field, even though the chemical(s) may not be mentioned 1n the title or abstract, but do appear 1n the original document. 7. On an experimental basis, a new searchable field will be created that will contain unlterms from the title field (TI), andunlterms from the keyword field (KW) which are the Index terms from TOXBIB, IPA, etc. This newfield will have the search mnemonic of (KW). This field could be used If a searcher wants terms primarily In either titles or keywords, and not the abstract.
Recommended publications
  • Properties and Units in Clinical Pharmacology and Toxicology

    Properties and Units in Clinical Pharmacology and Toxicology

    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
  • 33-Adrenoceptor-Mediated Relaxation Induced by Isoprenaline And

    33-Adrenoceptor-Mediated Relaxation Induced by Isoprenaline And

    J. Smooth Muscle Res. 33 : 99-106. 99 The )32 and [33-Adrenoceptor-Mediated Relaxation Induced by Isoprenaline and Salbutamol in Guinea Pig Taenia Caecum Katsuo KOIKE, Tsukasa IcHiNo, Takahiro HORINOUCHI and Issei TAKAYANAGI Departmentof Chemical Pharmacology, Toho University School of PharmaceuticalSciences, 2-2-1, Miyama,Funabashi, Chiba 274, Japan Abstract To understand the receptor subtypes responsible for /3adrenoceptormediated relaxa tion of guinea pig taenia caecum, we investigated the effects of isoprenaline and salbutamol . Isoprenaline and salbutamol caused dose-dependent relaxation of the guinea pig taenia caecum. Propranolol, bupranolol and butoxamine produced shifts of the concentration response curves for isoprenaline and salbutamol. Schild regression analyses carried out for propranolol against isoprenaline and salbutamol gave pA2 values of 8.43 and 8.88, respective ly. Schild regression analyses carried out for butoxamine against isoprenaline and sal butamol gave pA2 values of 6.46 and 6.68, respectively. Schild regression analyses carried out for bupranolol against isoprenaline and salbutamol gave pA2 values of 8.60 and 8.69, respectively. However, in the presence of 3 x 10' M atenolol, 10-4 M butoxamine and 10-6 M phentolamine to block the fir , /32 and a -adrenoceptor effects, respectively, Schild regression analyses carried out for bupranolol against isoprenaline and salbutamol gave pA2 values of 5.77 and 5.97, respectively. These results suggest that the relaxant responses to isoprenaline and salbutamol in the guinea pig taenia caecum are mediated by both the /.32 and the A-adrenoceptors. Key words : f2-adrenoceptor, A-adrenoceptor, isoprenaline, salbutamol , guinea pig taenia caecum Introduction The /3adrenoceptors were subclassified as and /32subtypes based on the agonist potency and tissue localization.
  • Us Anti-Doping Agency

    Us Anti-Doping Agency

    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
  • Guidance for the Format and Content of the Protocol of Non-Interventional

    Guidance for the Format and Content of the Protocol of Non-Interventional

    PASS information Title Metformin use in renal impairment Protocol version identifier Version 2 Date of last version of 30 October 2013 protocol EU PAS register number Study not registered Active substance A10BA02 metformin Medicinal product Metformin Product reference N/A Procedure number N/A Marketing authorisation 1A Farma, Actavis, Aurobindo, Biochemie, Bluefish, holder(s) Hexal, Mylan, Orifarm, Pfizer, Sandoz, Stada, Teva Joint PASS No Research question and To assess the use and safety of metformin in patients objectives with and without renal insufficiency in current clinical practice in at least two EU Member States. Country(-ies) of study Denmark, United Kingdom Author Christian Fynbo Christiansen, MD, PhD Page 1/214 Marketing authorisation holder(s) Marketing authorisation N/A holder(s) MAH contact person N/A Page 2/214 1. Table of Contents PASS information .......................................................................................................... 1 Marketing authorisation holder(s) .................................................................................... 2 1. Table of Contents ...................................................................................................... 3 2. List of abbreviations ................................................................................................... 4 3. Responsible parties .................................................................................................... 5 4. Abstract ..................................................................................................................
  • Partial Agreement in the Social and Public Health Field

    Partial Agreement in the Social and Public Health Field

    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
  • Novel Method of Administering Β-Blockers and Novel Dosage Forms Containing Same Anwar A

    Novel Method of Administering Β-Blockers and Novel Dosage Forms Containing Same Anwar A

    University of Kentucky UKnowledge Pharmaceutical Sciences Faculty Patents Pharmaceutical Sciences 1-31-1984 Novel Method of Administering β-Blockers and Novel Dosage Forms Containing Same Anwar A. Hussain University of Kentucky Right click to open a feedback form in a new tab to let us know how this document benefits oy u. Follow this and additional works at: https://uknowledge.uky.edu/ps_patents Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Hussain, Anwar A., "Novel Method of Administering β-Blockers and Novel Dosage Forms Containing Same" (1984). Pharmaceutical Sciences Faculty Patents. 124. https://uknowledge.uky.edu/ps_patents/124 This Patent is brought to you for free and open access by the Pharmaceutical Sciences at UKnowledge. It has been accepted for inclusion in Pharmaceutical Sciences Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact [email protected]. Unlted States Patent [191 [11] 4,428,883 Hussain [45] Jan. 31, 1984 [54] NOVEL METHOD OF ADMINISTERING 4,012,444 3/l977 Lunts ................................. .. 424/ 324 B-BLOCKERSF0 RMS Co NTA' AND, INING NOVEL SAME DOSAGE ' 4,250,163, , 1.1’;2/l981 llieoll’loldNagaioe a ......................................... ---- -~.. .. 424/14 [7 5 ] I nventor : An war A . Hussam,° Lexington' , Ky . FOREIGN PATENT DOCUMENTS [73] Assignee: The University of Kentucky Research . Foundation’ Lexington, Ky. 979389 1/ 1965 United Klngdom . I [21] APPL Nod 241,413 OTHER PUBLICATIONS . Stern, Arzmit. Forsch, vol. 24, 1974, pp. 70-71. [22] Flled‘ Mm‘- 6’ 1981 Black, Brit. J. PharmacoL, (1965) 25, pp. 577-591. [51] Int. Cl.3 ................... .. A61K 27/00; A61K 31/15; Prima'y Examiner_stanley L Friedman A61K 31/40; A61K 31/47; A61K 31/135; Attorney, Agent, or Firm-Burns, Doane, Swecker & A61K 31/165; A61K 31/435; A61K 31/475; Mathis A61K 47/00; C07C 143/90; CllD 1/28; C09F - 5 /()() [57] ABSTRACT [52] US.
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
  • An Insight on Analytical Profile on Bisoprolol Fumarate – a Selective Beta-1 Adrenoreceptor Blocker

    An Insight on Analytical Profile on Bisoprolol Fumarate – a Selective Beta-1 Adrenoreceptor Blocker

    DOI: 10.15415/jptrm.2017.52012 An Insight on Analytical Profile on Bisoprolol Fumarate – A Selective Beta-1 Adrenoreceptor Blocker AJINKYA G. DHANDAR, SURAJ R. CHAUDHARI, SAURABH B. GANORKAR, AMOD S. PATIL, SANJAY J. SURANA AND ATUL A. SHIRKHEDKAR* R.C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dist. Dhule, India *Email: [email protected] Received: June 15, 2017 | Revised: July 19, 2017 | Accepted: Sept. 22, 2017 Published online: Nov. 02, 2017 The Author(s) 2017. This article is published with open access at www.chitkara.edu.in/publications Abstract BF is Beta-adreno receptor antagonist and used as an Anti- Hypertensive Drug. BF gives the blocking action on β1-adrenergic receptors in the heart and vascular smooth muscle. The present review compiles the various approaches implemented for quantification of BF in bulk drug, pharmaceutical matrix and biological fluid. This review represents more than 50 analytical methods which include capillary electrophoresis, HPLC, HPTLC, UV-Spectroscopy, UPLC, impurity profiling and electrochemical methods implemented for estimation of BF as a single component as well as in multicomponent. Keyword: BF; Bioanalytical; UPLC/LC-MS; capillary electrophoresis; impurity profile 1. INTRODUCTION BF is an extremely discriminatory β1-adrenergic blocker [1]. BF is chemically: (RS)-1-[4-[[2-(1- Methylethoxy) ethoxy] methyl] phenoxy] -3-[(1 methyl ethyl) amino] propan-2-ol fumarate Figure 1. It is official in, USP. BF has similar structure to metoprolol, bopindolol, hydrochlorothiazide, atenolol [2]. Structure of BF, there is two substituents β at para position of benzene provide the activity of -selectivity, In which Journal of Pharmaceutical it has two substituents in para position of benzene which might be the Technology, Research and activity of β- selectivity [3].
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews

    Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews

    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
  • The V2 Receptor Antagonists

    The V2 Receptor Antagonists

    REVIEW New Horizons in the Pharmacologic Approach to Hyponatremia: The V2 Receptor Antagonists Biff F. Palmer, MD Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas. Disclosure: B.F. Palmer received an honorarium funded by an unrestricted educational grant from Otsuka America Pharmaceuticals, Inc., for time and expertise spent in the composition of this article. No editorial assistance was provided. He also receives speaker fees from Otsuka America Pharmaceuticals, Inc. This article provides an overview of the developing niche for vasopressin 2 receptor antagonists (‘‘vaptans’’) in the management of hyponatremia in clinical practice. Specific areas of focus include the physiological and clinical rationale for use of this class of medications (including advantages over older and less specific therapeutic modalities), the practical limitations to the use of these new drugs (including issues of tolerability, toxicity, risk, and cost), and the unanswered question of the extent to which correcting hyponatremia will improve clinical outcomes. Journal of Hospital Medicine 2010;5:S27–S32. VC 2010 Society of Hospital Medicine. KEYWORDS: arginine vasopressin, AVP receptor antagonists, conivaptan, tolvaptan, hyponatremia. Under normal circumstances, there is a balance between pressure or blood volume have no effect on AVP levels. water intake and water excretion such that plasma osmolal- However, once decreases in volume or pressure exceed this ity and the serum sodium (Naþ) concentration remain rela- value, baroreceptor-mediated signals provide persistent tively constant. The principal mechanism responsible for stimuli for AVP secretion. Baroreceptor-mediated AVP prevention of hyponatremia and hyposmolality is renal release will continue even when plasma osmolality falls water excretion.
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices

    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices

    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of